The upper extremity deep vein thrombosis (UEDVT) rate is increasing at the same time that the rate for insertions of peripherally inserted central catheters (PICCs) is on the rise. 1 For example, at one Midwestern hospital, whereas the rate of insertions remained constant for the first 4 years of the new millennium (0.8%-0.9%), the data from the most recent year demonstrated an increase of more than 25%. This PICC insertion rate corresponded to an increase in UEDVTs by 2.6%. Across settings, UEDVTs are associated with pain, further diagnostic testing, increased lengths of stays, worsening of comorbidities, and even death. 2 The insertion of a PICC is often indicated to deliver medications over extended periods. These treatments are frequently indicated for total parenteral nutrition (TPN, 10%), cancer (31%), and infection (46%). 3 The catheter may trigger the clotting process, however. 4, 5 Grove and Pevec 3 identified rates of UEDVT that varied from 1.5% (infection) to 5.1% (TPN) and 6.7% (cancer), whereas Allen et al 6 identified a 38% rate in patients after multiple venipunctures and the resultant vein trauma. In the United States, data on thrombus rates are inexact, but it is projected that the existing data underestimate the true incidence. 7 The risk factors for thrombi formation have been well studied for lower extremity DVTs and pulmonary emboli (PE). These factors include an interaction of genetic and acquired causes that disrupt the vascular endothelium, blood flow, and/or coagulation. [8] [9] [10] Little information is available, however, on whether the established risk factors for lower extremity DVTs or PE are effective to predict the occurrence in the upper extremities. Because the risk factors that predispose patients to thrombosis are extensive, the development of a multifactorial tool for the UEDVT was indicated.
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The overall purpose of this research was to develop an instrument to predict patients at high risk for UEDVT
• BACKGROUND to provide effective prophylaxis ( Figure 1) Few published studies have evaluated factors related to UEDVTs. As a result, factors associated with lower extremity DVTs and PE are explored. The risk factors from the Anand and Wells model are summarized first. 8 The thrombogenic effect of cancer, the rate of which varies between 3% and 18%, has been found in many studies. 1, 4, [17] [18] [19] [20] Significantly, when a patient presents with multiple DVTs, an evaluation for occult malignancy is indicated. 9, 12 Immobility is another risk factor for DVTs, perhaps related to venous stasis. 21 Pregnancy and puerperium are also risk factors for DVTs because of the increased levels of clotting factors, along with decreased fibrinolysis and levels of the natural anticoagulant, Protein S. 22 A patient's history of DVT has been associated with a higher risk for thrombus formation, especially when the patient has been exposed to high-risk conditions. 23 Caution also is recommended if there is a positive family history of hypercoagulability, DVT, or PE in first-degree relatives. 7, 9 Finally, endothelial damage of the vessel can be caused by repeated venipuncture, which increases thrombosis risk to the patient. 3, 23 Multiple venipunctures are associated with a higher thrombosis rate of 38%. 6 In addition to the variables identified in the Anand and Well's lower extremity DVT model, other risks were identified from the literature. These risk factors include age, diagnosis, intravenous (IV) medications, clotting factors, anticoagulant use, catheter characteristics, and arm characteristics. 8 Although age has been named a risk factor for DVT, it is postulated the association is actually caused by decreased mobility, decreased muscle tone, and increased morbidity, rather than age alone. 7, 9 Although no overall difference in thrombus rates by age or sex were found, 23 women experienced DVTs at younger ages, whereas the rate in men was higher at more advanced ages. 18 Medical conditions of diabetes and HTN have been associated with DVT formation-most likely related to the damage to the vascular endothelium. 6 Vessel damage also may result from the infusion of vesicants, irritants, or hyperosmolar solutions. 21 In one study, infusion of amphotericin B, considered an irritant, was found to be an independent risk factor for thrombosis because of chemical composition and its ability to cause vessel damage. 24 High levels of procoagulant factors, such as fibrinogen, prothrombin (Factor II), Factor VIII, Factor IX, and Factor XI, are associated with increased risk of thrombosis. 18, 23 Recent interest has focused on the use of d-dimer, because it may be elevated in conditions associated with thrombi. 7, 12, 18 Characteristics of the PICC may be associated with thrombosis. Although some authors have discussed the relationship between DVT and catheter diameter, others have not. 6, 25 Catheter materials within the vein are thrombogenic to varying levels. Stiffer catheter materials produce more intimal damage, which leads to thrombus formation. 26 In several studies, the stiffness of the catheter was thought to be a predictor of thrombogenicity. 26 Polyurethane, which is stiffer upon insertion, may be more thrombogenic than silicone. 26 The catheter tip location after insertion is under the control of the healthcare provider. 4 The tip should be located in the largest vein possible outside the heart and parallel with the long axis of the vein. 27 When the catheter tip ends before reaching the superior vena cava (SVC), vein curvatures, junctions and valves, and the vessel diameter increase the possibility of the tip disrupting the endothelial cell layer of the tunica intima. Rates of DVTs increase based on tip location from 10% (brachial) and 14% (basilic) to 57% (cephalic). 6 Preexisting arm characteristics of tenderness, swelling, and pitting edema can be indicative of a DVT, which warrants further evaluation before PICC insertion. 7 Although these factors individually may be associated with risk for venous thrombosis, the combination of factors may be more accurate at predicting risk. For example, a patient admitted for sepsis with a less-than-optimal catheter tip location would be more at risk for thrombus formation than if the catheter tip were ideally situated. 27 To provide significance for the development of a multifactorial risk factor prediction tool, an effective prophylaxis for thrombosis first must be determined. 23 Studies have demonstrated that risk of thrombi can be reduced by prophylactic low-risk anticoagulation therapy in high-risk surgical and medical patients. For example, postoperative hip replacement surgical patients have the fewest venographically demonstrable thrombi among medical and surgical patients when given low-molecular-weight heparin. 17 In patients with hematological malignancies, minidose warfarin may reduce thrombin generation without prolonging the prothrombin time. 19 In other oncology patients with CVCs, the rate of thrombosis was reduced from 38% to 19% in patients who received warfarin daily. 17 In this study, there were no side effects of bleeding. A further study showed that metastatic breast cancer patients who receive chemotherapy overall have reduced thrombosis rates by 85%, with no excessive bleeding when taking warfarin. 17 At one 300-bed Midwest community hospital, PICCs have been placed at the bedside by PICC-qualified registered nurses since 1991. An early vascular access program was developed and instituted in 2006 to address the issue of patients with risk factors for UEDVTs (M. Santiago, M. Seeley, unpublished data, 2005). A clinical prediction guide-the PICC insertion screening form-was developed to predict thrombosis formation and was composed of risk factors identified in the literature. 8 Patients with 3 or more risk factors were categorized as high risk.
The modified Seldinger technique, with ultrasound or fluoroscopy, was used for all insertions. The insertion veins used were as follows: basilica (90%), median cubital
• METHODS
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(6%), and brachial (4%). Vein condition was assessed indirectly by physical exam and ultrasound at the time of insertion. Fifty-three percent of the catheters placed were 4-French silicone, 36% were 5-French silicone, and 10% were 6-French polyurethane. Final tip terminations were SVC (81%), subclavian (7%), axillary (6%), and brachycephalic (5%). After Institutional Review Board approval, an evaluation of characteristics of all patients receiving PICC insertions over 6 months was conducted by blinded chart review. The data collection form developed for the medical record extractions included all the factors associated in the literature with DVTs (Figure 2) . The extraction was conducted by 2 PICC-qualified RNs, with each data point checked by both researchers for accuracy.
SPSS for Windows (Version 13) was used for data management and statistical analysis. Because the variables had statistically non-normal distributions, nonparametric statistical methods were used to analyze the data. For the univariate analyses, the Mann-Whitney test was used to compare patients with upper extremity DVTs and patients without upper extremity DVTs with respect to noncategorical variables. The chi-square test of association and Fisher's exact test were conducted to compare these groups with respect to percentages. Fisher's exact test was used when the expected frequencies were too small to allow use of the chi-square test. For the multivariable analyses, backward elimination logistic regression was done to develop a model to predict whether a patient would develop an upper extremity DVT during the hospital stay. The variables in Table 1 were used as independent variables in the logistic regression analyses. A 0.05 significance level was used for all statistical tests. No one-sided statistical tests were done. PICC insertion screening form. Tab. 1 Of the 233 patients in the study, 17 (7%) developed a UEDVT during their hospital stay. Table 1 shows demographic and clinical characteristics of the patients in the study and P values to test for differences between patients who developed a UEDVT during their hospital stay and patients who did not. By univariate analysis, patients who developed a UEDVT were more likely to have the following characteristics: osteomyelitis as the reason the PICC was inserted, use of an anticoagulant at home or in the hospital, recent bedridden status, localized tenderness along the distribution of the deep venous system, entire arm swelling, HTN, obesity, and higher UEDVT risk factor checklist scores. Fourteen patients (6%) in this study had osteomyelitis as a diagnosis. Backward elimination logistic regression, using the variables in Table 1 , produced a model for predicting the development of UEDVT during the hospital stay. This model contained the following statistically significant independent variables: recent bedridden status, localized tenderness along the distribution of the deep venous system, smoking, osteomyelitis as the reason the PICC was inserted, and use of an anticoagulant at home or in the hospital (Table 2 ). In this model, the presence of each of these characteristics increased the risk of UEDVT. These logistic regression results can be used to construct an instrument for predicting development of UEDVT during the hospital stay, as shown in Table 3 . The scores for the 5 items in the instrument are added to obtain a total score that can range from 0 to 66. If the total score is 20 or more, the instrument predicts that the patient will develop a UEDVT during the hospital stay. Scores less than 20 predict no UEDVT during the hospital stay. For the sample of 233 patients used to develop the instrument, this cutoff value resulted in high sensitivity, specificity, and negative predictive values: 88.2%, 81.5%, and 98.9%, respectively. The positive predictive value was low: 27.3%. The total percentage of cases that were correctly classified
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• RESULTS was 82%. This instrument performed better than the UEDVT risk factor checklist score when used to predict UEDVT during the hospital stay. When UEDVT risk factor checklist scores of 3 and 4 were used to predict development of UEDVT during the hospital stay, the sensitivity, specificity, and negative and positive predictive values were 52.9%, 89.4%, 96.0%, and 28.1%, respectively, with 86.7% of the cases correctly classified.
In 2006, the mean cost of care for a patient with osteomyelitis receiving 3 months of prophylaxis was $14,300 during a 9-day length of stay at this hospital. This cost was compared to a similar patient who did not receive prophylaxis and developed a thrombus. The patient without prophylaxis would endure a second hospitalization of 6 days with an additional cost of $14,112. This cost estimate included standard treatment with enoxaparin for 6 months. The net comparison was $14,300 to $25,829, with a cost savings for 1 patient with a thrombus of more than $12,000.
This study resulted in the development of the UEDVT prediction tool. The study identified high-risk from specific factors described in the literature, such as recent bedridden status and localized tenderness along the upper extremity deep venous system. 7-,9,12 Joffe et al 12 showed a correlation between smoking and UEDVT formation. No studies were located that discussed the high risk associated with osteomyelitis in the authors' study, however. This infection has the most significant association with the development of a UEDVT. The finding of anticoagulant use as a predictor of UEDVT is likely due to the earlier identification of the patient's risk at home or at the hospital.
Implications for Practice
The development of the UEDVT prediction tool was undertaken to develop a protocol for thrombus prophylaxis to reduce the risks of UEDVT development in patients with PICC insertions. If the UEDVT prediction tool were used as an indicator of a need for thrombus prophylaxis with this population of patients, 18% would have received prophylaxis for thrombi. Two patients would not have been identified by this tool, however, and the tool may need revision after further evaluation. Implementing a prophylaxis protocol using the UEDVT prediction tool would likely be associated with an 88% decreased incidence of UEDVTs in patients with PICCs. The cost of prophylaxis is nearly half the cost of a UEDVT for a single patient. In addition to the financial cost, there remains the unquantified personal burden of the complication in patients for whom it was preventable.
Implications for Further Research
Further testing on a larger sample of patients is needed to validate and refine this instrument. Additional research may lead to modifications of the instrument that will maintain its high sensitivity, specificity, and negative predictive value while improving its positive predictive value.
Further research on the long-term costs and benefits of anticoagulant use with patients having PICCs is planned. The optimal anticoagulant therapy for these patients will be evaluated. The development of research from practice questions has resulted in a tool with the potential to decrease the morbidity and mortality of UEDVTs associated with PICCs. This is one more study that lends support to the value of nursing research that originates from the bedside.
